Work

61353 Real-World Skin Clearance and Quality of Life With Risankizumab in Patients Eligible for Systemic Therapy per International Psoriasis Council Criteria

Year: 2025

Type: article

Study design: Observational Study

Source: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2025.05.1133

Authors: Bruce Strober, Manish Patel, Mark I. Kaldas, Greg St. John, Vishvas Garg, Adam P. Sima, Thomas Eckmann, Alicia Beeghly, April Armstrong

Institutions: Yale University, AbbVie (United States), University of California, Los Angeles

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413870962

FWCI:

Cites:

Cited by:

Related to: 10